Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Removal of Doravirine by Hemodialysis in HIV-Infected Patients With End-Stage Renal Disease (ESRD)

Trial Profile

Removal of Doravirine by Hemodialysis in HIV-Infected Patients With End-Stage Renal Disease (ESRD)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doravirine (Primary) ; Antiretrovirals
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms DORA-HD
  • Most Recent Events

    • 15 Apr 2022 Results evaluating the effect of haemodialysis on doravirine concentrations in people living with HIV undergoing routine haemodialysis, published in the Journal of Antimicrobial Chemotherapy
    • 16 Feb 2022 Results assessing the effect of hemodialysis on doravirine clearance HIV-infected patients undergoing routine hemodialysis, presented at the 29th Conference on Retroviruses and Opportunistic Infections
    • 06 Jul 2021 Status changed from recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top